



**AVID RADIOPHARMACEUTICALS TO PRESENT AT COWEN AND COMPANY  
30TH ANNUAL HEALTH CARE CONFERENCE ON MONDAY, MARCH 8**

**Philadelphia, PA, March 2, 2010** – [Avid Radiopharmaceuticals, Inc.](#), a leader in the development of products with the potential for earlier and more effective detection, diagnosis and monitoring of brain disorders, today announced that [Franz F. Hefti, PhD](#), Avid's Chief Scientific Officer, will present at the Cowen and Company 30<sup>th</sup> Annual Health Care Conference on Monday, March 8, 2010 at 10:00am EST in the MIT Room, 3<sup>rd</sup> Floor at the Boston Marriott Copley Place in Boston, Massachusetts. The presentation will be 25 minutes followed by Q&A.

Dr. Hefti has more than 20 years experience in the pharmaceutical industry and over a decade experience in academia. At the conference, he will provide attendees with an update on Phase III clinical trials and commercialization efforts for Avid's amyloid imaging compound <sup>18</sup>F-AV-45 (AV-45). This tracer is the most advanced compound of its type in development for imaging amyloid plaque in the brain associated with Alzheimer's Disease. In 2009, AV-45 entered a pivotal registration study using a unique trial design that was based upon recommendations by the FDA peripheral and CNS advisory committee.

Avid's second program, <sup>18</sup>F-AV-133 (AV-133) PET imaging of the vesicular monoamine transporter 2 (VMAT2) in patients with suspected dopaminergic degeneration, is currently in Phase II clinical trials. AV-133 has also been shown to be a marker for beta cells of the pancreas in preclinical studies. The compound is now in Phase I studies to test the ability of this molecular imaging agent to distinguish type 1 and type 2 diabetes subjects from healthy normal individuals based on a PET scan of the pancreas.

**About Avid Radiopharmaceuticals, Inc.**

Avid Radiopharmaceuticals is a leader in the development of molecular imaging products with the potential for earlier and more effective detection, diagnosis and monitoring of major chronic human diseases. Based in Philadelphia, PA, the company is a pioneer in the development of molecular imaging agents for Alzheimer's disease that could lead to earlier diagnosis and better evaluation of drugs designed to prevent or reverse amyloid plaque build-up in the brain. Avid is currently conducting Phase III clinical studies of <sup>18</sup>F-AV-45 for imaging amyloid plaques in Alzheimer's disease, and is in Phase I and II trials with <sup>18</sup>F-AV-133 for imaging the vesicular monoamine transporter (VMAT2) in diseases involving dopaminergic degeneration (Parkinson's disease and Dementia with Lewy Bodies) and beta cell dysfunction (Type I and Type II Diabetes Mellitus). For more information, please visit [www.avidrp.com](http://www.avidrp.com).

**CONTACT:**

Richard A. Baron  
Chief Financial Officer  
baron@avidrp.com  
215-298-0723

###